In this Review, Cichowski and colleagues provide an overview of combinatorial strategies designed to treat RAS-driven cancers that are based on four concepts that include vertical pathway inhibition, co-targeting RAS and adaptive survival pathways, co-targeting downstream or converging pathways and capitalizing on other cancer-associated vulnerabilities.

In this Review, Paul et al. provide an overview of therapeutic antibodies as an important modality in cancer therapy today. They summarize the different approaches used by antibodies to target cancer cells including those of immune checkpoint inhibitors, bispecific antibodies and antibody–drug conjugates, as well as describing current strategies aimed at improving their efficacy and reducing toxicities.

The mechanisms of how pH-dependent cell death, alkaliptosis, is regulated are incompletely understood. Chen et al. now demonstrate that the cholesterol biosynthesis protein CYP51A1 suppresses alkaliptosis induced by the opioid analgesic JTC801.

In this Tools of the Trade article, Ziwei Xue describes the development and use of scAtlasVAE, a deep learning framework that integrates single-cell RNA-sequencing data from CD8⁺ T cells across studies.

Salmonella infections, prevalent globally, correlate with increased risk of cancer, particularly gallbladder and colon cancers. In this Comment, Stévenin and Neefjes highlight the need for further investigation into Salmonella-driven cellular transformation.

Glycolysis-dependent T cell function is hindered by glucose scarcity in the tumour microenvironment. Now in Cancer Cell, Schild et al. engineered T cells to utilize fructose via GLUT5, enhancing their metabolic activity and cytotoxicity.

In this Tools of the Trade article, Kenta Ninomiya describes the development of ImAge, an imaging-based approach that captures age-related trajectories of chromatin and epigenetic marks in single nuclei for longitudinal analyses.

Understanding the complex relationship between ageing and cancer is crucial for cancer risk prediction. In this Comment, LaBarge and Binder explore how tissue-specific ageing biomarkers can enhance cancer risk stratification and highlight the need for tailored approaches in assessing susceptibility across different tissues.